Colored x-ray of the pelvic region shows a fractured femur (red) caused by a fall. A lack of clinical trials and limited pharmaceutical options mean that management of this complication poses ...

A machine learning model using basic clinical data can predict PH risk, identifying key predictors like low hemoglobin and elevated NT-proBNP. Researchers have developed a machine learning model that ...

Each month, Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Each year there are 3.9 ...

In a recently published guidance, the ASN aims to help patients with kidney disease navigate the risks inherent to potassium ...

Patients with chronic kidney disease (CKD) are no more likely to be included in trials of medications aimed at reducing cardiovascular risks now than they were about two decades ago, resulting in ...

On October 28, 2025, Akebia Therapeutics announced it will not proceed with the VALOR clinical trial for vadadustat in non-dialysis chronic kidney disease patients following an unsuccessful alignment ...

As expected, the in-hospital mortality was somewhat lower for the non-ST-elevation MI population (compared with those with non-ST-elevation MI), with a range of 1.8% to 13.4%., with CKD patients 2.1 ...

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also ...

Only 1 in 4 patients with type 2 diabetes receive guideline-recommended annual screening for chronic kidney disease, decreasing their likelihood of renoprotective treatment. Guideline-recommended ...

Patients with chronic kidney disease (CKD) who receive a gadolinium-based contrast agent (GBCA) have a low risk of developing nephrogenic systemic fibrosis (NSF), a systematic review and meta-analysis ...

Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDACAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a ...